ASN Podcast

Congressional Affairs Manager Zach Kribs joins hosts Tod Ibrahim and David White to discuss what to expect this year in both federal regulatory and Congressional health care policy.

In this episode, discover what Nisha Bansal, MD, FASN, and Ankur Shah, MD, FASN, consider this year's highlights. They will dive into Kidney Week highlights, community interactions, and kidney health.

In this episode, Raad Bin Zakir Chowdhury, MD, FASN, and Deepak Chandramohan, MD, discuss their experiences with the evolving directions and tools for kidney care treatment with Angie S. Lobo, MD, moderating the conversation.

In this episode, George L. Bakris, MD, MA, FASN, and Duc H. Quach, MD, discuss day 2 of Kidney Week.

In this episode, Joel M. Topf, MD, hosts the discussion with Jennie Lin, MD, MS, FASN and patient advocate, Precious McCowan, MS, as they dive into experiences with kidney disease and the key takeaways from the Early Program sessions.

David White and Lauren Ahearn interview colleagues Zach Kribs and Rachel Meyer about HRSA's OPTN Modernization Initiative and H.R. 2544. Contact HRSA about the OPTN Modernization Initiative here- https://www.hrsa.gov/optn-modernization/contact

With the start of summer comes the start of the busy policy season. Tod Ibrahim, David White, and Lauren Ahearn discuss the recent SCOTUS decision on affirmative action, the CY2024 ESRD PPS QIP proposed rule, and ASN's upcoming Transplant Advocacy Day.

In this Regulatory and Legislative update David White and Tod Ibrahim discuss Medicaid redetermination, concurrent dialysis and hospice, and the case of Braidwood Management vs. Becerra.

David White speaks with ASN President Michelle A. Josephson, MD, FASN, and ASN Strategic Policy Advisor to the Executive Vice President Rachel Meyer about changes within HRSA, big-picture issues within transplant nephrology, and more.

In this episode, Tod and David discuss recent updates from within the Department of Health and Human Services, including changes in the OPTN, the back-and-forth between the FDA and CMS on the accelerated approval of drugs, and more.